

Molgen signs license deal for China

16 February 2018 | News

The signed agreement with Oncologie includes the development, manufacture and commercialization of lefitolimod in China and a planned global co-development program.



The biopharmaceutical company Molgen recently announced the signing of a license deal for the Chinese territory and a global co-development agreement between Molgen and Oncologie Inc. for its lead compound lefitolimod. The signed agreement is conditional upon an initial payment of EUR 3 million received by Molgen.

Oncologie is an oncology-focused drug development company with headquarters in Boston and operations in Shanghai. The company is backed by top-tier international investors and has the objective to develop novel personalized medicines in the field of immuno-oncology. The signed agreement with Oncologie includes the development, manufacture and commercialization of lefitolimod in China and a planned global co-development program.

The license agreement includes sublicense rights under which Molgen grants Oncologie an exclusive license for the development, manufacturing and commercialization for Molgen's lead compound lefitolimod in the following territory: China, Hong Kong and Macao, Taiwan and Singapore.